Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
Author:
Affiliation:
1. Research and Development, Pharmaceuticals Bayer AG Berlin Germany
Publisher
Wiley
Subject
Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1002/1878-0261.12693
Reference86 articles.
1. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes
2. The long tail of oncogenic drivers in prostate cancer
3. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer
4. Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC
5. CHD1 regulates cell fate determination by activation of differentiation-induced genes
Cited by 30 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. SLC4A4 is a novel driver of enzalutamide resistance in prostate cancer;Cancer Letters;2024-08
2. CRISPR genome-wide screening identifies PAK1 as a critical driver of ARSI cross-resistance in prostate cancer progression;Cancer Letters;2024-04
3. Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status;International Journal of Molecular Sciences;2024-03-07
4. Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape;Molecular Therapy;2024-03
5. Dual targeting of the androgen receptor and PI3K/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis;Molecular Oncology;2024-01-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3